Imatinib Mesylate 400mg
- First-Line treatment of CML CP Significantly Improved QOL
- Overall est. survival rate* was 83.3% with Imatinib compared to 65.6% with interferon alfa plus cytarabine
- Approx. 82.8% Patients completed cytogenetic response.
Indication | Dosage |
Philadelphia chromosome positive chronic myeloid leukaemia (Chronic phase) | 400 mg/day |
Philadelphia chromosome positive chronic myeloid leukaemia ( Accelerated phase or Blast crisis) | 600 mg/day |
Philadelphia chromosome positive chronic myeloid leukaemia (Paediatric) | 340 mg/m2/day |
(not exceeding 800 mg/m2/day) | |
Philadelphia chromosome positive + Acute lymphoblastic leukaemia | 600 mg/day |
Philadelphia chromosome positive + Acute lymphoblastic leukaemia (Paediatric) | 340 mg/m2 daily |
not to exceed the total dose of 600 mg | |
Myelodysplastic/ Myeloproliferative disorders | 400 mg/day |
Aggressive systemic mastocytosis | 100 to 400 mg/day (escalation) |
Hypereosinophilic syndrome (HES) / Chronic eosinophilic leukaemia (CEL) | 100 to 400 mg/day (escalation) |
Dermatofibrosarcoma protuberans | 800 mg/day |
Metastatic and/or unresectable Gastrointestinal stromal tumours | 400 mg/day |
Adjuvant treatment of Gastrointestinal stromal tumours | 400 mg/day |